A central point in the profile of Cladribine is the relationship between its molecular action and the cancer setting in which it is used. Adenosine deaminase-resistant purine analog that accumulates in lymphoid cells and causes DNA damage. The drug interferes with nucleotide metabolism or related cellular pathways, limiting the ability of actively dividing tumor cells to synthesize or process essential DNA building blocks. The record identifies it as Purine nucleoside analog within Chemotherapy; Purine Analog and lists Hairy Cell Leukemia among the associated tumor types. The principal indications are Hairy cell leukemia; selected lymphoid malignancies. Regimen examples include Cladribine monotherapy; hairy cell leukemia regimens. The combination context matters: depending on the disease, the agent may be used alone or alongside other systemic treatments as specified in the database. Its clinical role is defined by the disease-specific regimen, treatment intent, and patient-selection criteria associated with the listed indications. Any biomarker or disease-state requirement included in the indication should be considered when interpreting the entry. The same broad therapeutic class can contain medicines with different targets and therefore different clinical uses. This description intentionally remains descriptive rather than prescriptive, with no patient-specific dosing or treatment instructions. Current labels and applicable oncology guidelines should be consulted to confirm present-day indications and combinations.